This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Risedronate

Authoring team

Risedronate is a pyridinyl bisphosphonate. It is licensed for prevention and treatment of both postmenopausal and corticosteroid-induced osteoporosis at a recommended dose of 5mg daily.

The overall incidence of adverse effects in trials with risedronate is similar to placebo, even for upper GI events. Patients with active GI disease or on NSAIDs were not excluded from these trials.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.